Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Post-herpetic Neuralgia Followed by a 52-Week Open-label Extension

NCT02318719 is registered in ClinicalTrials.gov with Daiichi Sankyo Co., Ltd. as lead sponsor.

NCT NCT02318719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02318719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Post-herpetic Neuralgia Followed by a 52-Week Open-label Extension
Lead sponsor
Daiichi Sankyo Co., Ltd.
Phase
Not applicable
Overall status
Completed
Start date
January 31, 2015
Completion date
May 25, 2017
Enrollment
765 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

post-herpetic neuralgia